OncoZenge AB operates as a pharmaceutical company. The firm offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The compay was founded on June 15, 2020 and is headquartered in Bromma, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company